ArQule Company Profile (NASDAQ:ARQL)

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.75 (132.92% upside)

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
Show:
DateFirmActionRatingPrice TargetActions
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/27/2015Royal Bank Of CanadaUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for ArQule (NASDAQ:ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214($0.12)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2012($0.09)$0.07ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ArQule (NASDAQ:ARQL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.08)($0.08)($0.08)
Q3 20161($0.09)($0.09)($0.09)
Q4 20161($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ArQule (NASDAQ:ARQL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ArQule (NASDAQ:ARQL)
DateHeadline
07/21/16 02:35 PMChecking in on Stock Volatility for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily
07/20/16 10:02 PMWere Analysts Bullish ArQule, Inc. (NASDAQ:ARQL) This Week? - Consumer Eagle
07/20/16 06:00 AMArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 - [GlobeNewswire] - BURLINGTON, Mass., July 20, 2016-- ArQule, Inc. today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday, August 3, 2016. The Company will hold ...
07/19/16 02:34 PMArQule (ARQL) Announces Presentation of ARQ 531 Preclinical Data - StreetInsider.com
07/19/16 02:34 PMArqule Incorporated (NASDAQ:ARQL) Shorts Decreased by 4.65% After Short Covering - Press Telegraph
07/18/16 03:00 PMArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference - [GlobeNewswire] - Data supports further preclinical and clinical research in BTK sensitive and ibrutinib resistant malignancies. BURLINGTON, Mass., July 18, 2016-- ArQule, Inc. today announced the first public presentation ...
07/15/16 06:51 PMStrong Sell Calls For ArQule, Inc. (NASDAQ:ARQL) At 0 - Investor Newswire
07/15/16 06:51 PMShares Experiencing a Downtrend: ArQule Inc. (NASDAQ:ARQL) - TGP
07/13/16 02:38 PMArQule, Inc. (ARQL) Updated Price Targets - FTSE News
07/12/16 08:05 PMHow Analysts Feel About ArQule, Inc. (NASDAQ:ARQL)? - Consumer Eagle
07/12/16 06:17 AMConsensus Target and Stock Rating Report: ArQule, Inc. (NASDAQ:ARQL) - Telanagana Press
07/09/16 10:38 AMArqule Incorporated (NASDAQ:ARQL) Sellers Increased By 13.75% Their Shorts - Press Telegraph
07/08/16 07:44 PMIs $5 Within Reach For ArQule, Inc. (NASDAQ:ARQL)? - Investor Newswire
07/08/16 02:35 PMEye Catching Stocks: ArQule Inc. (NASDAQ:ARQL), Dehaier Medical Systems Limited (NASDAQ:DHRM), Lipocine Inc ... - KC Register
07/08/16 02:35 PMBullish Movers: SemiLEDs Corporation (NASDAQ:LEDS), ArQule Inc. (NASDAQ:ARQL), China Commercial Credit, Inc ... - KC Register
07/06/16 02:37 PMArQule, Inc. (ARQL) Current Analyst Ratings - Fiscal Standard
07/06/16 07:22 AMShares Dropping Lower in Session: ArQule Inc. (NASDAQ:ARQL) - Telanagana Press
07/05/16 02:32 PMShare Volatility in Focus: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily
07/05/16 06:00 AMArQule to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 12, 2016 - [GlobeNewswire] - BURLINGTON, Mass., July 05, 2016-- ArQule, Inc. today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present ...
07/04/16 02:32 PMBroker Outlook For The Week Ahead ArQule, Inc. (ARQL) - Fiscal Standard
07/02/16 02:36 PMCompany Stock Lower on the Week ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily
07/02/16 02:36 PMNew Broker Ratings For ArQule, Inc. (ARQL) - FTSE News
07/01/16 07:48 PMArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity
07/01/16 02:34 PMArQule, Inc. (NASDAQ:ARQL) Expected to Reach Highs Of $5 - Investor Newswire
07/01/16 02:34 PMHere's What The ArQule, Inc. (ARQL) Data Really Means - Insider Monkey (blog)
07/01/16 11:55 AMHere’s What The ArQule, Inc. (ARQL) Data Really Means -
07/01/16 10:37 AMHere’s What The ArQule, Inc. (NASDAQ:ARQL) Data Really Means
06/30/16 02:45 PMArQule (ARQL) Announces Prelim. Data on ARQ 087 Phase 1/2; Anticancer Activity Observed - StreetInsider.com
06/30/16 02:45 PMUpdate on Stock Volatility for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily
06/30/16 02:45 PMCheck on Unusual Volume for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily
06/30/16 10:27 AMArQule Presents Anti-Cancer Activity For Its ARQ 087 In Rare Liver Cancer
06/30/16 08:40 AMArQule's ARQ 087 shows evidence of anticancer activity in Phase 1/2 study in rare bile duct cancer; shares up 10% premarket -
06/26/16 02:30 PMArQule, Inc. (ARQL) Broker Price Targets For The Coming Week - Fiscal Standard
06/25/16 07:54 AMStrong Sell Calls Recommendations For ArQule, Inc. (NASDAQ:ARQL) At 0 - Investor Newswire
06/23/16 10:23 AMArQule To Present Data From Phase1/2 Trial Of ARQ 087
06/20/16 01:02 PMETF’s with exposure to ArQule, Inc. : June 20, 2016 -
06/20/16 04:00 AMArQule: Advancing a Deep and Diverse Clinical Stage Pipeline - [Accesswire] - NEW YORK, NY / ACCESSWIRE / June 20, 2016 / Rising Tide Equity Research, LLC announced today the release of its Initial Equity Report on ArQule, Inc (NASDAQ: ARQL), a biopharmaceutical company engaged ...
06/19/16 07:18 AMThis Weeks Broker Views For ArQule, Inc. (ARQL) - Fiscal Standard
06/17/16 02:32 PMStrong Buy Calls Count For ArQule, Inc. (NASDAQ:ARQL) At 0 - Investor Newswire
06/15/16 07:23 AMRecently Issued Stock Ratings For ArQule, Inc. (ARQL) - Fiscal Standard
06/08/16 10:24 AMValeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss -
06/01/16 08:41 PMInsiders Are Gradually Buying ArQule Inc. (NASDAQ:ARQL) - HNN - Insiders Are Gradually Buying ArQule Inc. (NASDAQ:ARQL)HNNAccording to the latest SEC filings, insiders at ArQule Inc. (NASDAQ:ARQL) have increased their position in the stock by 2.33% over the past 6 months. Insiders now own 1.10% of total outstanding shares. There are both legal and illegal types of insider ...and more »
05/26/16 07:09 PMArQule, Inc. (ARQL) Updated Broker Price Targets - Share Trading News - ArQule, Inc. (ARQL) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of ArQule, Inc. (ARQL). The latest reports which are currently in issue on Thursday 26th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...
05/26/16 11:12 AMARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/26/16 12:08 AMInsiders Are Gradually Buying ArQule Inc. (NASDAQ:ARQL) - Wall Street Hints and News - Insiders Are Gradually Buying ArQule Inc. (NASDAQ:ARQL)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at ArQule Inc. (NASDAQ:ARQL) have increased their position in the stock by 2.24% over the past 6 months. Insiders now own 1.10% of total outstanding shares. There are both legal and illegal types of insider ...and more »
05/24/16 12:07 AMArQule, Inc. (NASDAQ:ARQL) Impact Score At 100 - Stocks Daily - ArQule, Inc. (NASDAQ:ARQL) Impact Score At 100Stocks DailyAlpha One explored various online articles released on ArQule, Inc. (NASDAQ:ARQL), and it set a daily sentiment score of 0.56 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued ...and more »
05/17/16 12:56 PMArQule, Inc. :ARQL-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/08/16 08:45 PMArQule, Inc. (ARQL) Broker Price Targets For The Coming Week - Share Trading News - ArQule, Inc. (ARQL) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of ArQule, Inc. (ARQL). The latest reports which are currently in issue on Sunday 8th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...
05/06/16 07:19 PMArQule, Inc. (NASDAQ:ARQL) ABR Of 2.5 - RealistInvestor.com - ArQule, Inc. (NASDAQ:ARQL) ABR Of 2.5RealistInvestor.comThere are numerous brokerages operating in the market, and each one of them uses a different process to prepare the research reports on a stock. As a result, investors have to study more than one research report before taking an investment call on a stock.and more »
05/05/16 12:27 AMEARNINGS SUMMARY: Details of ArQule Inc. Q1 Earnings Report - Below are the earnings highlights for ArQule Inc. (ARQL): -Earnings: -$4.98 million in Q1 vs. -$4.55 million in the same period last year. -EPS: -$0.08 in Q1 vs. -$0.07 in the same period last year. -Analysts projected -$0.07 per share -Revenue ...

Social

About ArQule

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARQL
  • CUSIP: 04269E10
Key Metrics:
  • Previous Close: $1.61
  • 50 Day Moving Average: $1.74
  • 200 Day Moving Average: $1.71
  • P/E Ratio: N/A
  • P/E Growth: -0.94
  • Market Cap: $114.41M
  • Beta: 1.47
  • Current Year EPS Consensus Estimate: $-0.34 EPS
  • Next Year EPS Consensus Estimate: $-0.23 EPS
Additional Links:
ArQule (NASDAQ:ARQL) Chart for Tuesday, July, 26, 2016